{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:20:35Z","timestamp":1787019635993,"version":"build-2736575974"},"reference-count":45,"publisher":"American Society of Hematology","issue":"9","license":[{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5,14]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>While awaiting confirmatory results, empiric therapy for patients suspected to have immune thrombotic thrombocytopenic purpura (iTTP) provides benefits and also accrues risks and costs. Rapid assays for ADAMTS13 may be able to avoid the cost and risk exposure associated with empiric treatment. We conducted, to our knowledge, the first cost-effectiveness evaluation of testing strategies with rapid vs traditional ADAMTS13 assays in patients with intermediate- to high-risk PLASMIC scores, with and without caplacizumab use. We built a Markov cohort simulation with 4 clinical base-case analyses: (1) intermediate-risk PLASMIC score with caplacizumab; (2) intermediate-risk PLASMIC score without caplacizumab; (3) high-risk PLASMIC score with caplacizumab; and (4) high-risk PLASMIC score without caplacizumab. Each of these evaluated 3 testing strategies: (1) rapid assay (&amp;lt;1-hour turnaround); (2) in-house fluorescence resonance energy transfer (FRET)\u2013based assay (24-hour turnaround); and (3) send-out FRET-based assay (72-hour turnaround). The primary outcome was the incremental net monetary benefit reported over a 3-day time horizon and across accepted willingness-to-pay thresholds in US dollars per quality-adjusted life-year (QALY). While accruing the same amount of QALYs, the rapid assay strategy saved up to $46\u2009820 (95%\u00a0CI, $41\u2009961-$52\u2009486) per patient tested. No parameter variation changed the outcome. In probabilistic sensitivity analyses, the rapid assay strategy was favored in 100% (3 base cases and scenario analyses) and 99% (1 base-case and scenario analysis) across 100\u2009000 Monte Carlo iterations within each. Rapid ADAMTS13 testing for patients with intermediate- or high-risk PLASMIC scores yields significant per patient cost savings, achieved by reducing the costs associated with unnecessary therapeutic plasma exchange and caplacizumab therapy in patients without iTTP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024012608","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T12:00:34Z","timestamp":1710849634000},"page":"2279-2289","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Cost-effectiveness of rapid vs in-house vs send-out ADAMTS13 testing for immune thrombotic thrombocytopenic purpura"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7972-7605","authenticated-orcid":false,"given":"Cecily","family":"Allen","sequence":"first","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4430-1860","authenticated-orcid":false,"given":"Satoko","family":"Ito","sequence":"additional","affiliation":[{"name":"2Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1172-2159","authenticated-orcid":false,"given":"Ayesha","family":"Butt","sequence":"additional","affiliation":[{"name":"3Department of Internal Medicine, Yale University School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7634-2363","authenticated-orcid":false,"given":"Adriana","family":"Purcell","sequence":"additional","affiliation":[{"name":"4Yale University School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhys","family":"Richmond","sequence":"additional","affiliation":[{"name":"4Yale University School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1785-2245","authenticated-orcid":false,"given":"Christopher A.","family":"Tormey","sequence":"additional","affiliation":[{"name":"5Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2046-127X","authenticated-orcid":false,"given":"Harlan M.","family":"Krumholz","sequence":"additional","affiliation":[{"name":"6Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT"},{"name":"7Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Cuker","sequence":"additional","affiliation":[{"name":"8Department of Medicine and Department of Pathology & Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1624-4427","authenticated-orcid":false,"given":"George","family":"Goshua","sequence":"additional","affiliation":[{"name":"2Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT"},{"name":"7Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,5,14]]},"reference":[{"issue":"21","key":"2024051415215238500_bib1","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood"},{"issue":"10","key":"2024051415215238500_bib2","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/pbc.24612","article-title":"Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features","volume":"60","author":"Reese","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"2024051415215238500_bib3","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1111\/jth.15006","article-title":"ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"2024051415215238500_bib4","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1182\/asheducation-2015.1.631","article-title":"What's new in the diagnosis and pathophysiology of thrombotic thrombocytopenic purpura","volume":"2015","author":"Sadler","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"2024051415215238500_bib5","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study","volume":"4","author":"Bendapudi","year":"2017","journal-title":"Lancet Haematol"},{"issue":"4","key":"2024051415215238500_bib6","doi-asserted-by":"crossref","first-page":"e10208","DOI":"10.1371\/journal.pone.0010208","article-title":"Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience","volume":"5","author":"Coppo","year":"2010","journal-title":"PLoS One"},{"issue":"8","key":"2024051415215238500_bib7","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/ajh.26241","article-title":"Laboratory testing for ADAMTS13: Utility for TTP diagnosis\/exclusion and beyond","volume":"96","author":"Favaloro","year":"2021","journal-title":"Am J Hematol"},{"issue":"1","key":"2024051415215238500_bib8","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1365-2141.2005.05420.x","article-title":"FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay","volume":"129","author":"Kokame","year":"2005","journal-title":"Br J Haematol"},{"issue":"11","key":"2024051415215238500_bib9","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1111\/trf.14230","article-title":"ADAMTS13 test and\/or PLASMIC clinical score in management of acquired thrombotic thrombocytopenic purpura: a cost-effective analysis","volume":"57","author":"Kim","year":"2017","journal-title":"Transfusion"},{"issue":"5","key":"2024051415215238500_bib10","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/vox.12912","article-title":"Potential impact of a delayed ADAMTS13 result in the treatment of thrombotic microangiopathy: an economic analysis","volume":"115","author":"Kim","year":"2020","journal-title":"Vox Sang"},{"issue":"11","key":"2024051415215238500_bib11","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1055\/s-0039-1696718","article-title":"Evaluation of a new, rapid, fully automated assay for the measurement of ADAMTS13 activity","volume":"119","author":"Valsecchi","year":"2019","journal-title":"Thromb Haemost"},{"issue":"3","key":"2024051415215238500_bib12","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s11239-020-02086-8","article-title":"Evaluation of a rapid turn-over, fully-automated ADAMTS13 activity assay: a method comparison study","volume":"50","author":"Stratmann","year":"2020","journal-title":"J\u00a0Thromb Thrombolysis"},{"issue":"1","key":"2024051415215238500_bib13","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/rth2.12461","article-title":"Diagnosis and follow-up of thrombotic thrombocytopenic purpura with an automated chemiluminescent ADAMTS13 activity immunoassay","volume":"5","author":"Beranger","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"2","key":"2024051415215238500_bib14","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/jth.15157","article-title":"A\u00a0multicenter laboratory assessment of a new automated chemiluminescent assay for ADAMTS13 activity","volume":"19","author":"Favaloro","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"2024051415215238500_bib15","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/ijlh.13414","article-title":"Multicentric evaluation of the new HemosIL Acustar\u00ae chemiluminescence ADAMTS13 activity assay","volume":"43","author":"Pascual","year":"2021","journal-title":"Int J Lab Hematol"},{"issue":"11","key":"2024051415215238500_bib16","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1007\/s00134-019-05736-5","article-title":"Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura","volume":"45","author":"Azoulay","year":"2019","journal-title":"Intensive Care Med"},{"issue":"1","key":"2024051415215238500_bib34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2165\/00019053-200725010-00002","article-title":"Rates and probabilities in economic modelling: transformation, translation and appropriate application","volume":"25","author":"Fleurence","year":"2007","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"2024051415215238500_bib17","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/bloodadvances.2020001834","article-title":"Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis","volume":"5","author":"Peyvandi","year":"2021","journal-title":"Blood Adv"},{"issue":"8","key":"2024051415215238500_bib18","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1111\/trf.13654","article-title":"Treatment with or without plasma exchange for patients with acquired thrombotic microangiopathy not associated with severe ADAMTS13 deficiency: a propensity score-matched study","volume":"56","author":"Li","year":"2016","journal-title":"Transfusion"},{"issue":"1","key":"2024051415215238500_bib19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/rth2.12160","article-title":"Thrombotic thrombocytopenic purpura: toward targeted therapy and precision medicine","volume":"3","author":"Coppo","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"13","key":"2024051415215238500_bib20","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1182\/blood.2020007599","article-title":"Real-world experience with caplacizumab in the management of acute TTP","volume":"137","author":"Dutt","year":"2021","journal-title":"Blood"},{"key":"2024051415215238500_bib21","author":"Kn\u00f6bl","year":"9-13  2022"},{"issue":"24","key":"2024051415215238500_bib22","doi-asserted-by":"crossref","first-page":"6219","DOI":"10.1182\/bloodadvances.2022008028","article-title":"Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura","volume":"6","author":"Izquierdo","year":"2022","journal-title":"Blood Adv"},{"issue":"11","key":"2024051415215238500_bib23","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1111\/jth.15048","article-title":"Definition of major bleeding: prognostic classification","volume":"18","author":"Franco","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"issue":"Suppl 1","key":"2024051415215238500_bib24","first-page":"65s","article-title":"Adverse effects of plasma transfusion","volume":"52","author":"Pandey","year":"2012","journal-title":"Transfusion"},{"issue":"1","key":"2024051415215238500_bib25","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1537-2995.2011.03247.x","article-title":"Transfusion-associated circulatory overload after plasma transfusion","volume":"52","author":"Narick","year":"2012","journal-title":"Transfusion"},{"issue":"12","key":"2024051415215238500_bib26","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1111\/j.1537-2995.2012.03646.x","article-title":"Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011 (CME)","volume":"52","author":"Som","year":"2012","journal-title":"Transfusion"},{"issue":"4","key":"2024051415215238500_bib27","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1378\/chest.09-0841","article-title":"Long-term survival and quality of life after transfusion-associated pulmonary edema in critically ill medical patients","volume":"137","author":"Li","year":"2010","journal-title":"Chest"},{"issue":"1","key":"2024051415215238500_bib28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s15010-014-0689-y","article-title":"Attributable mortality of central line associated bloodstream infection: systematic review and meta-analysis","volume":"43","author":"Ziegler","year":"2015","journal-title":"Infection"},{"key":"2024051415215238500_bib29","unstructured":"Centers for Medicare & Medicaid Services\n          . Hospital Outpatient PPS. Accessed 17 September 2023. https:\/\/www.cms.gov\/medicare\/payment\/prospective-payment-systems\/hospital-outpatient\/addendum-a-b-updates."},{"issue":"7","key":"2024051415215238500_bib30","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1182\/blood.2020006052","article-title":"Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura","volume":"137","author":"Goshua","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2024051415215238500_bib31","doi-asserted-by":"crossref","first-page":"e12711","DOI":"10.1002\/rth2.12711","article-title":"Economic impact of a rapid, on-demand ADAMTS-13 activity assay for the diagnosis of thrombotic thrombocytopenic purpura","volume":"6","author":"White","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"2","key":"2024051415215238500_bib32","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/trf.13359","article-title":"Effect of ADAMTS13 activity turnaround time on plasma utilization for suspected thrombotic thrombocytopenic purpura","volume":"56","author":"Connell","year":"2016","journal-title":"Transfusion"},{"key":"2024051415215238500_bib33","author":"Centers for Medicare & Medicaid Services","year":"2023"},{"issue":"1","key":"2024051415215238500_bib35","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s001340000760","article-title":"A\u00a0cost-effectiveness analysis of stays in intensive care units","volume":"27","author":"Sznajder","year":"2001","journal-title":"Intensive Care Med"},{"issue":"1","key":"2024051415215238500_bib36","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","article-title":"EuroQol: the current state of play","volume":"37","author":"Brooks","year":"1996","journal-title":"Health Policy"},{"key":"2024051415215238500_bib37","unstructured":"Consumer Price Index. Accessed 1 September 2023. https:\/\/data.bls.gov\/cgi-bin\/cpicalc.pl."},{"issue":"1","key":"2024051415215238500_bib38","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/M20-1392","article-title":"A\u00a0health opportunity cost threshold for cost-effectiveness analysis in the United States","volume":"174","author":"Vanness","year":"2021","journal-title":"Ann Intern Med"},{"issue":"7","key":"2024051415215238500_bib39","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1111\/j.1538-7836.2005.01436.x","article-title":"The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency","volume":"3","author":"Terrell","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"issue":"10","key":"2024051415215238500_bib40","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"issue":"6","key":"2024051415215238500_bib41","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura","volume":"325","author":"Rock","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2024051415215238500_bib42","doi-asserted-by":"crossref","first-page":"E161","DOI":"10.1002\/ajh.26926","article-title":"Treatment delay and outcomes in elderly thrombotic thrombocytopenic purpura patients: A nationwide analysis","volume":"98","author":"Mahmoud","year":"2023","journal-title":"Am J Hematol"},{"issue":"7543","key":"2024051415215238500_bib43","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/bmj.38737.607558.80","article-title":"Bias in published cost effectiveness studies: systematic review","volume":"332","author":"Bell","year":"2006","journal-title":"BMJ"},{"issue":"6","key":"2024051415215238500_bib44","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.2020008021","article-title":"A\u00a0regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP","volume":"137","author":"Coppo","year":"2021","journal-title":"Blood"},{"issue":"14","key":"2024051415215238500_bib45","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: an international working group consensus report","volume":"137","author":"Cuker","year":"2021","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/9\/2279\/2224974\/blooda_adv-2024-012608-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/9\/2279\/2224974\/blooda_adv-2024-012608-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T11:23:05Z","timestamp":1715685785000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/9\/2279\/515347\/Cost-effectiveness-of-rapid-vs-in-house-vs-send"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,14]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,5,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024012608","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,14]]}}}